NuVasive, Inc. (NUVA)

Check out top investors' recommendation for NUVA
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
66.29
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The company’s products focus on applications for spine fusion surgery. It offers products for the thoracolumbar spine and the cervical spine primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines three categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve detection and avoidance systems, and intra-operative monitoring support services for insight into the nervous system during spine and other surgeries; MaXcess, an integrated split-blade retractor system; and various specialized implants. The company’s biologic products include allograft, a donated human tissue; FormaGraft, a collagen synthetic product; Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; and AttraX, a synthetic bone graft material. It also offers solutions for cervical fusion surgery, including allograft and CoRoent implants, as well as cervical plating and posterior fixation products. In addition, the company’s products comprise PCM device, a motion preserving total disc replacement device; and XL TDR, a mechanical total disc replacement solution. NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Glenn Novarro RBC Capital Markets Buy   Feb 11, '19     70.00  Feb 11, '20  N/A 
Jeff Johnson Robert W. Baird & Co., Inc. Buy   Feb 11, '19     60.00  Feb 11, '20  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Feb 10, '19     70.00  Feb 10, '20  N/A 
Michael Matson Mizuho Securities USA Buy   Jan 08, '19     61.00  Jan 08, '20  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Jan 07, '19     70.00  Jan 07, '20  N/A 
Jeff Johnson Robert W. Baird & Co., Inc. Buy   Jan 07, '19     63.00  Jan 07, '20  N/A 
Glenn Novarro RBC Capital Markets Buy   Nov 27, '18     70.00  Nov 27, '19  N/A 
Jeff Johnson Robert W. Baird & Co., Inc. Buy   Sep 27, '18     82.00  Sep 27, '19  N/A 
Josh Jennings Cowen And Company Buy   Sep 11, '18     80.00  Sep 11, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Aug 14, '18     75.00  Aug 14, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Aug 01, '18     67.00  Aug 01, '19  N/A 
Raj Denhoy Jefferies & Co. Buy   Aug 01, '18     67.00  Aug 01, '19  N/A 
Bob Hopkins BofA Merrill Lynch Sell   Jun 27, '18     56.00  Jun 27, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Mar 15, '18     90.00  Mar 15, '19  N/A 
Matthew Taylor National Bank Financial Buy   Feb 27, '18     62.00  Feb 27, '19  N/A 
Josh Jennings Cowen And Company Buy   Feb 27, '18     62.00  Feb 27, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Feb 27, '18     70.00  Feb 27, '19  N/A 
Matthew Taylor National Bank Financial Buy   Jan 08, '18     66.00  Jan 08, '19  N/A 
Michael Matson Mizuho Securities USA Buy   Jan 04, '18     71.00  Jan 04, '19  N/A 
Matthew O'Brien William Blair & Company, L.L.C. Buy   Dec 15, '17     90.00  Dec 15, '18  N/A 
< previous12345